Akari Therapeutics CEO exercises pre-funded warrants

The 174,000-option grant is subject to forfeiture if shareholders do not approve a proposed equity-plan amendment.

Rhea-AI Filing Summary

Akari Therapeutics Plc CEO Abizer Gaslightwala exercised pre-funded warrants on October 14, 2026, acquiring 19,333 ADSs and 7,733 ADSs at an exercise price of $0.0004 per ADS. The warrants became exercisable upon shareholder approval obtained March 2, 2026. On August 18, 2026, he was granted options to purchase 174,000 ADSs at $7.899 per ADS, expiring August 18, 2036; the grant is subject to forfeiture if shareholder approval of a proposed equity-plan amendment is not obtained, and vesting is subject to continued service.

Insider Trade Summary

27,066 shares exercised/converted

Exercise 5 txns

Insider Gaslightwala Abizer

Role CEO

Type	Security	Shares	Price	Value
Exercise	Pre-Funded Warrant to Purchase ADSs F4, F6, F2, F3	19,333	$16.16	$312K
Exercise	Pre-Funded Warrant to Purchase ADSs F5, F6, F2, F3	7,733	$16.16	$125K
Exercise	American Depositary Shares representing Ordinary Shares	19,333	$0.0004	$7.73
Exercise	American Depositary Shares representing Ordinary Shares	7,733	$0.0004	$3.09
Grant/Award	Stock Option (Right to Buy) F1	174,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 174,000 contracts (Direct); Pre-Funded Warrant to Purchase ADSs — 0 contracts (Direct); American Depositary Shares representing Ordinary Shares — 41,173 shares (Direct)

Footnotes (6)

1. F1. On August 18, 2026, the Reporting Person was granted an option to purchase 174,000 American Depository Shares ("ADSs"). This option grant is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 2.08% of the grant for each one-month anniversary from March 18, 2026 (the "Accrual Date") that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the four-year anniversary of the Accrual Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
2. F2. The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
3. F3. The pre-funded warrants remain exercisable until fully exercised.
4. F4. On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 19,333 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 19,333 ADSs.
5. F5. On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Private Placement Pre-Funded Warrants") to purchase up to 7,733 ADSs, at a purchase price of $16.16 per Private Placement Pre-Funded Warrant, and (ii) warrants to purchase up to 7,733 ADSs.
6. F6. The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.

Key Figures

ADSs acquired from note-exchange pre-funded warrants: 19,333 ADSs ADSs acquired from private-placement pre-funded warrants: 7,733 ADSs Pre-funded warrant exercise price: $0.0004 per ADS +3 more

6 metrics

ADSs acquired from note-exchange pre-funded warrants 19,333 ADSs Exercise on October 14, 2026

ADSs acquired from private-placement pre-funded warrants 7,733 ADSs Exercise on October 14, 2026

Pre-funded warrant exercise price $0.0004 per ADS Warrant exercises on October 14, 2026

Stock options granted 174,000 options Grant on August 18, 2026

Option exercise price $7.899 per ADS Options granted on August 18, 2026

Option expiration date August 18, 2036 Options granted on August 18, 2026

Key Terms

pre-funded warrants, Accrual Date, equity incentive plan, vesting

4 terms

pre-funded warrants financial

"The pre-funded warrants became exercisable upon shareholder approval"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Accrual Date financial

"March 18, 2026 (the "Accrual Date")"

equity incentive plan financial

"proposed amendment to the Issuer's equity incentive plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"This option will vest with respect to 2.08% of the grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AKTX ADSs did the CEO acquire from warrant exercises?

Abizer Gaslightwala acquired 19,333 ADSs in one exercise and 7,733 ADSs in another on October 14, 2026, at an exercise price of $0.0004 per ADS.

How does Abizer Gaslightwala's AKTX option grant vest?

Beginning on the date shareholder approval is obtained, the option vests with respect to 2.08% of the grant for each one-month anniversary from March 18, 2026, that had elapsed before approval. The remainder vests in equal monthly installments beginning on the 18th day of the month after approval, until fully vested on the four-year anniversary of March 18, 2026, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 05:20 PM EDT Accepted by SEC EDGAR 10/16/2026 - 05:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gaslightwala Abizer

(Last) (First) (Middle)

C/O AKARI THERAPEUTICS PLC

401 EAST JACKSON STREET, SUITE 3300

(Street)

TAMPA FLORIDA 33602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares representing Ordinary Shares	10/14/2026		M		19,333	A	$0.0004	33,440	D
American Depositary Shares representing Ordinary Shares	10/14/2026		M		7,733	A	$0.0004	41,173	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.899	08/18/2026		A		174,000		(1)	08/18/2036	American Depositary Shares representing Ordinary Shares	174,000	$0	174,000	D
Pre-Funded Warrant to Purchase ADSs	$0.0004	10/14/2026		M			19,333	(2)	(3)	American Depositary Shares representing Ordinary Shares	19,333	$16.16(4)(6)	0	D
Pre-Funded Warrant to Purchase ADSs	$0.0004	10/14/2026		M			7,733	(2)	(3)	American Depositary Shares representing Ordinary Shares	7,733	$16.16(5)(6)	0	D

Explanation of Responses:

1. On August 18, 2026, the Reporting Person was granted an option to purchase 174,000 American Depository Shares ("ADSs"). This option grant is subject to forfeiture if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan ("Shareholder Approval") is not obtained. Beginning on the date of Shareholder Approval, this option will vest with respect to 2.08% of the grant for each one-month anniversary from March 18, 2026 (the "Accrual Date") that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the four-year anniversary of the Accrual Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

2. The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.

3. The pre-funded warrants remain exercisable until fully exercised.

4. On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 19,333 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 19,333 ADSs.

5. On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Private Placement Pre-Funded Warrants") to purchase up to 7,733 ADSs, at a purchase price of $16.16 per Private Placement Pre-Funded Warrant, and (ii) warrants to purchase up to 7,733 ADSs.

6. The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.

	/s/ Abizer Gaslightwala, as Attorney-in-Fact	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)